December 24, 2008 -- Drug resistant strains of pathogens are an urgent unmet need, but currently, despite the large market opportunity, there are no new classes of antibiotics in clinical development. ProteLight Pharmaceuticals of China and BioAMPs International of Denver, CO want to change that. Together, the two companies own the worldwide rights to V13K, a peptide-based antibiotic currently in pre-clinical development. As a peptide, V13K attacks the membrane of the pathogen, instead of targeting a metabolic pathway as a small-molecule drug would do. More details...
